British Association of Dermatologists

Response to Health Technology Appraisal
Review of NICE Technology Appraisal Guidance No.321; Dabrafenib for treating advanced unresectable or metastatic BRAFV600 mutation-positive melanoma

Proposal to move the existing guidance to the static list

British Association of Dermatologists
Therapy & Guidelines and Skin Cancer sub-committees

On behalf of the British Association of Dermatologists, thank you for the opportunity to comment on the Health Technology Appraisal.

The British Association of Dermatologists agrees with the proposal to move guidance TA321: dabrafenib for treating advanced unresectable or metastatic BRAFV600 mutation-positive melanoma to the static list.

Dr Pamela McHenry
Chair, Therapy & Guidelines sub-committee